Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab:A case report and review of literature  

作　　者：Bo Deng Rui Gao Bing Yang Wen-Bing Lei Ming-Fang Xue Ji-Shi Wang Peng Zhao 

机构地区：[1]Department of Haematology,Guizhou Hospital,The First Affiliated Hospital of Sun Yat-sen University,Guiyang 550001,Guizhou Province,China [2]Department of Hematology,The Affiliated Hospital of Guizhou Medical University,Guiyang 550001,Guizhou Province,China [3]School of Clinical Medicine,Guizhou Medical University,Guiyang 550001,Guizhou Province,China [4]Department of Hematology,The Affiliated Hospital of Guizhou Medical University,Hematological Institute of Guizhou Province,Guiyang 550001,Guizhou Province,China

出　　处：《World Journal of Clinical Cases》2024年第24期5604-5612,共9页世界临床病例杂志

基　　金：Natural Science Foundation of Guizhou Province,China,No.397.

摘　　要：BACKGROUND Allogeneic hematopoietic stem cell transplantation(Allo-HSCT)is currently the only viable method of curing patients with acute myeloid leukaemia.In 30%to 50%of patients,donors and recipients have some level of ABO blood group incompatibility.ABO blood group incompatibility can cause antibodies against the donor's red blood cells to persist in the recipient's body,resulting in a delay of several months in the recovery of red blood cells.A number of different treatments have been reported for post-transplant pure red cell aplastic anaemia(PRCA),such as plasmapheresis,donor lymphocyte infusions,anti-thymocyte globulin,rituximab and steroids.CASE SUMMARY A 41-year-old female diagnosed with acute myeloid leukaemia underwent peripheral blood allogeneic haematopoietic stem cell transplantation in November 2013 from an HLA matched unrelated donor.The donor was AB-positive and the recipient was O-positive.The patient was diagnosed with PRCA three months after receiving the donor stem cell transplant.After failing multiple lines of therapy,the patient applied for daratumumab.After receiving three doses of daratumumab,the patient developed a reticulocyte response and no longer required CONCLUSION The use of daratumumab anti-CD38 for the remove of plasma cells is safe and effective and may be tried for refractory patients with PRCA after undergoing allo-HSCT for ABO incompatibility.

关 键 词：TRANSPLANTATION PRCA Daratumumab LEUKEMIA blood-group Case report 

分 类 号：R457.7[医药卫生—治疗学] R692[医药卫生—临床医学]